WEKO3
アイテム
経口糖尿病薬の適応と使用法(シリーズ「糖尿病の治療」(2))
http://hdl.handle.net/10470/26816
http://hdl.handle.net/10470/26816708981d3-21a1-439b-8680-7adf47e395d5
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
KJ00006018442.pdf (619.1 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||
|---|---|---|---|---|---|---|---|---|
| 公開日 | 2010-08-10 | |||||||
| タイトル | ||||||||
| タイトル | 経口糖尿病薬の適応と使用法(シリーズ「糖尿病の治療」(2)) | |||||||
| 言語 | ||||||||
| 言語 | jpn | |||||||
| 資源タイプ | ||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||
| 資源タイプ | journal article | |||||||
| 別タイトル | ||||||||
| その他のタイトル | How to Use Oral Hypoglycemie Agents in Diabetic Patients?(Series "Treatment of Diabetes Mellitus" (2)) | |||||||
| 著者名 |
佐倉, 宏
× 佐倉, 宏
|
|||||||
| 著者別名 | ||||||||
| 識別子Scheme | WEKO | |||||||
| 識別子 | 299043 | |||||||
| 姓名 | SAKURA, Hiroshi | |||||||
| 出版者 | ||||||||
| 出版者 | 東京女子医科大学学会 | |||||||
| 受付日付 | ||||||||
| 日付 | 2010-08-10 | |||||||
| 日付タイプ | Created | |||||||
| ISSN | ||||||||
| 収録物識別子タイプ | ISSN | |||||||
| 収録物識別子 | 0040-9022 | |||||||
| NCID | ||||||||
| 収録物識別子タイプ | NCID | |||||||
| 収録物識別子 | AN00161368 | |||||||
| 書誌情報 |
東京女子医科大学雑誌 巻 75, 号 5, p. 91-95, 発行日 2005-05 |
|||||||
| 著者版フラグ | ||||||||
| 出版タイプ | VoR | |||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||
| 抄録 | ||||||||
| 内容記述タイプ | Abstract | |||||||
| 内容記述 | Various kinds of oral hypoglycemic agents (OHA) are currently available for the treatment of type 2 diabetes mellitus. OH As are only recommended after the introduction of diet and exercise therapy for several months, because life-style modification generally improves glucose control effectively. Sulfonylureas are often prescribed for individuals with fasting hyperglycemia and insulin-deficiency, whereas biguanides or thiazolidinediones are often used among insulin-resistant diabetic patients. α-Glucosidase inhibitors or fast-acting insulin secreting drugs are suitable for patients with post-prandial hyperglycemia. OHA treatment target is to maintain a HbAlc level below 6.5% without hypoglycemia. Combination of two or more OH As is often effective in cases where mono-therapy yields unfavorable result. Large-scale clinical trials showed that sulfonylurea or biguanide postponed diabetic complications. However, research evidence on the effectiveness of OHAs, especially among the Japanese diabetic population, is still insufficient. We analyzed the database of OHAs prescription and the clinical information of patients at Tokyo Women's Medical University Hospital. We found that OHA therapy was only successful when patients complied with diet and exercise therapy. Thus, type 2 diabetes treatment remains a difficult challenge. | |||||||
| 著者所属 | ||||||||
| 東京女子医科大学糖尿病センター | ||||||||
| 著者キーワード | ||||||||
| 主題Scheme | Other | |||||||
| 主題 | oral hypoglycemic agents (OHA) | |||||||
| 著者キーワード | ||||||||
| 主題Scheme | Other | |||||||
| 主題 | type 2 diabetes mellitus | |||||||
| 著者キーワード | ||||||||
| 主題Scheme | Other | |||||||
| 主題 | insulin secretion | |||||||
| 著者キーワード | ||||||||
| 主題Scheme | Other | |||||||
| 主題 | insulin resistance | |||||||
| 著者キーワード | ||||||||
| 主題Scheme | Other | |||||||
| 主題 | α-glucosidase inhibitor | |||||||
